Elutia to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025
Elutia (Nasdaq: ELUT), a drug-eluting biomatrix technologies company, has scheduled its second quarter 2025 financial results release for Thursday, August 14, 2025, after market close.
The company will host a conference call and webcast at 5:00 p.m. Eastern Time on the same day. Management will be available to discuss the results, with both domestic and international dial-in numbers provided for investor participation.
[]Elutia (Nasdaq: ELUT), un'azienda specializzata in tecnologie di biomatrice a rilascio di farmaci, ha programmato la pubblicazione dei suoi risultati finanziari del secondo trimestre 2025 per giovedì 14 agosto 2025, dopo la chiusura del mercato.
La società terrà una conference call e una webcast alle 17:00 ora orientale dello stesso giorno. Il management sarà disponibile per discutere i risultati, con numeri di telefono sia nazionali che internazionali per la partecipazione degli investitori.
Elutia (Nasdaq: ELUT), una empresa de tecnologías de biomatriz con liberación de fármacos, ha programado la publicación de sus resultados financieros del segundo trimestre de 2025 para el jueves 14 de agosto de 2025, después del cierre del mercado.
La compañía realizará una llamada conferencia y una transmisión en vivo a las 5:00 p.m. hora del Este ese mismo día. La gerencia estará disponible para discutir los resultados, con números de teléfono tanto nacionales como internacionales para la participación de los inversores.
Elutia (나스닥: ELUT)는 약물 방출 바이오매트릭스 기술 회사로, 2025년 2분기 재무 실적 발표를 2025년 8월 14일 목요일 장 마감 후로 예정했습니다.
회사는 같은 날 동부 표준시 오후 5시에 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다. 경영진이 결과에 대해 논의할 예정이며, 국내외 투자자 참여를 위한 전화 접속 번호가 제공됩니다.
Elutia (Nasdaq : ELUT), une entreprise spécialisée dans les technologies de biomatrice à libération de médicament, a programmé la publication de ses résultats financiers du deuxième trimestre 2025 pour le jeudi 14 août 2025, après la clôture du marché.
La société organisera une conférence téléphonique et une diffusion en direct à 17h00 heure de l'Est le même jour. La direction sera disponible pour discuter des résultats, avec des numéros d'appel nationaux et internationaux fournis pour la participation des investisseurs.
Elutia (Nasdaq: ELUT), ein Unternehmen für medikamentenfreisetzende Biomatrix-Technologien, hat die Veröffentlichung seiner Finanzergebnisse für das zweite Quartal 2025 für Donnerstag, den 14. August 2025, nach Börsenschluss, geplant.
Das Unternehmen wird am selben Tag um 17:00 Uhr Eastern Time eine Telefonkonferenz und Webcast veranstalten. Das Management steht zur Verfügung, um die Ergebnisse zu besprechen, wobei sowohl nationale als auch internationale Einwahlnummern für Investoren bereitgestellt werden.
- None.
- None.
GAITHERSBURG, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its second quarter 2025 financial results after market close on Thursday, August 14, 2025. Members of the Company’s management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day.
The conference call can be accessed using the following information:
Webcast: Click here
U.S. Investors: 877-407-8029
International Investors: 201-689-8029
Conference ID: 13754773
Please log in approximately 10 minutes prior to the scheduled start time. A live and archived webcast of the event will be available on the “Investors” section of the Elutia website at http://investors.elutia.com/.
About Elutia
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.
Investors:
Matt Steinberg
FINN Partners
matt.steinberg@finnpartners.com
This press release was published by a CLEAR® Verified individual.
